These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 32464186)

  • 1. Potential of immunotherapies in the mediation of antileukemic responses for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) - With a focus on Dendritic cells of leukemic origin (DC
    Ansprenger C; Amberger DC; Schmetzer HM
    Clin Immunol; 2020 Aug; 217():108467. PubMed ID: 32464186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Interferon (IFN)α in "Cocktails" for the Generation of (Leukemia-derived) Dendritic Cells (DCleu) From Blasts in Blood From Patients (pts) With Acute Myeloid Leukemia (AML) and the Induction of Antileukemic Reactions.
    Hirn Lopez A; Deen D; Fischer Z; Rabe A; Ansprenger C; Stein K; Vogt V; Schick J; Kroell T; Kraemer D; Kolb HJ; Tischer J; Schmid C; Schmetzer H
    J Immunother; 2019 Jun; 42(5):143-161. PubMed ID: 31090655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Granulocyte-Macrophage-Colony-Stimulating-Factor Combined with Prostaglandin E1 Create Dendritic Cells of Leukemic Origin from AML Patients' Whole Blood and Whole Bone Marrow That Mediate Antileukemic Processes after Mixed Lymphocyte Culture.
    Unterfrauner M; Rejeski HA; Hartz A; Bohlscheid S; Baudrexler T; Feng X; Rackl E; Li L; Rank A; Filippini Velázquez G; Schmid C; Schmohl J; Bojko P; Schmetzer H
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum-free generation and quantification of functionally active Leukemia-derived DC is possible from malignant blasts in acute myeloid leukemia and myelodysplastic syndromes.
    Kufner S; Fleischer RP; Kroell T; Schmid C; Zitzelsberger H; Salih H; de Valle F; Treder W; Schmetzer HM
    Cancer Immunol Immunother; 2005 Oct; 54(10):953-70. PubMed ID: 15789235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion of AML-blasts to leukemia-derived dendritic cells (DCleu) in 'DC-culture-media' shifts correlations of released chemokines with antileukemic T-cell reactions.
    Merle M; Fischbacher D; Liepert A; Grabrucker C; Kroell T; Kremser A; Dreyssig J; Freudenreich M; Schuster F; Borkhardt A; Kraemer D; Koehne CH; Kolb HJ; Schmid C; Schmetzer HM
    Immunobiology; 2021 May; 226(3):152088. PubMed ID: 33838552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of Leukaemia-Derived Dendritic Cells (DC
    Schwepcke C; Klauer LK; Deen D; Amberger DC; Fischer Z; Doraneh-Gard F; Gunsilius C; Hirn-Lopez A; Kroell T; Tischer J; Weinmann M; Werner JO; Rank A; Schmid C; Schmetzer HM
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35955486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective and Successful Quantification of Leukemia-Specific Immune Cells in AML Patients' Blood or Culture, Focusing on Intracellular Cytokine and Degranulation Assays.
    Schutti O; Klauer L; Baudrexler T; Burkert F; Schmohl J; Hentrich M; Bojko P; Kraemer D; Rank A; Schmid C; Schmetzer H
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PGE
    Amberger DC; Doraneh-Gard F; Gunsilius C; Weinmann M; Möbius S; Kugler C; Rogers N; Böck C; Ködel U; Werner JO; Krämer D; Eiz-Vesper B; Rank A; Schmid C; Schmetzer HM
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31533251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dendritic Cells of Leukemic Origin: Specialized Antigen-Presenting Cells as Potential Treatment Tools for Patients with Myeloid Leukemia.
    Amberger DC; Schmetzer HM
    Transfus Med Hemother; 2020 Dec; 47(6):432-443. PubMed ID: 33442338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells.
    Grabrucker C; Liepert A; Dreyig J; Kremser A; Kroell T; Freudenreich M; Schmid C; Schweiger C; Tischer J; Kolb HJ; Schmetzer H
    J Immunother; 2010 Jun; 33(5):523-37. PubMed ID: 20463595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic cells (DCs) can be successfully generated from leukemic blasts in individual patients with AML or MDS: an evaluation of different methods.
    Kremser A; Dressig J; Grabrucker C; Liepert A; Kroell T; Scholl N; Schmid C; Tischer J; Kufner S; Salih H; Kolb HJ; Schmetzer H
    J Immunother; 2010; 33(2):185-99. PubMed ID: 20139775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antileukemic T-cell responses can be predicted by the composition of specific regulatory T-cell subpopulations.
    Schick J; Vogt V; Zerwes M; Kroell T; Kraemer D; Köhne CH; Hausmann A; Buhmann R; Tischer J; Schmetzer H
    J Immunother; 2013 May; 36(4):223-37. PubMed ID: 23603857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic Cell-Triggered Immune Activation Goes along with Provision of (Leukemia-Specific) Integrin Beta 7-Expressing Immune Cells and Improved Antileukemic Processes.
    Rackl E; Li L; Klauer LK; Ugur S; Pepeldjiyska E; Seidel CL; Gunsilius C; Weinmann M; Doraneh-Gard F; Reiter N; Plett C; Amberger DC; Bojko P; Kraemer D; Schmohl J; Rank A; Schmid C; Schmetzer HM
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of T-cells after stimulation with leukemia-derived dendritic cells (DC) from patients with acute myeloid leukemia (AML) or myeloid dysplastic syndrome (MDS) is predictive for their leukemia cytotoxic potential.
    Liepert A; Grabrucker C; Kremser A; Dreyssig J; Ansprenger C; Freudenreich M; Kroell T; Reibke R; Tischer J; Schweiger C; Schmid C; Kolb HJ; Schmetzer H
    Cell Immunol; 2010; 265(1):23-30. PubMed ID: 20663492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Volatile Phases Derived from Serum, DC, or MLC Culture Supernatants to Deduce a VOC-Based Diagnostic Profiling Strategy for Leukemic Diseases.
    Baudrexler T; Boeselt T; Li L; Bohlscheid S; Boas U; Schmid C; Rank A; Schmohl J; Koczulla R; Schmetzer HM
    Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leukemia derived dendritic cell (DC
    Pepeldjiyska E; Li L; Gao J; Seidel CL; Blasi C; Özkaya E; Schmohl J; Kraemer D; Schmid C; Rank A; Schmetzer HM
    Immunobiology; 2022 Jul; 227(4):152237. PubMed ID: 35749805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vitro Generated Dendritic Cells of Leukemic Origin Predict Response to Allogeneic Stem Cell Transplantation in Patients With AML and MDS.
    Freudenreich M; Tischer J; Kroell T; Kremser A; Dreyßig J; Beibl C; Liepert A; Kolb HJ; Schmid C; Schmetzer H
    J Immunother; 2022 Feb-Mar 01; 45(2):104-118. PubMed ID: 34864807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leukaemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with myelodysplasia: a methodological approach under serum-free culture conditions.
    Kufner S; Zitzelsberger H; Kroell T; Pelka-Fleischer R; Salem A; de Valle F; Schmid C; Schweiger C; Kolb HJ; Schmetzer HM
    Scand J Immunol; 2005 Jul; 62(1):75-85. PubMed ID: 16091127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paramunity-inducing Factors (PINDs) in dendritic cell (DC) cultures lead to impaired antileukemic functionality of DC-stimulated T-cells.
    Ansprenger C; Vogt V; Schick J; Hirn-Lopez A; Vokac Y; Harabacz I; Braeu M; Kroell T; Karenberg A; Kolb HJ; Schmetzer H
    Cell Immunol; 2018 Jun; 328():33-48. PubMed ID: 29580554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Various 'dendritic cell antigens' are already expressed on uncultured blasts in acute myeloid leukemia and myelodysplastic syndromes.
    Dreyssig J; Kremser A; Liepert A; Grabrucker C; Freudenreich M; Schmid C; Kroell T; Scholl N; Tischer J; Kufner S; Salih H; Kolb HJ; Schmetzer HM
    Immunotherapy; 2011 Sep; 3(9):1113-24. PubMed ID: 21913833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.